Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance
Guardado en:
Autores principales: | Masarret Fazili, Scott M. Stevens, Scott C. Woller |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/19588b5652a247dfaf9921b1cf187c33 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Heritable Thrombophilia in Venous Thromboembolism in Northern Pakistan: A Cross-Sectional Study
por: Maria Khan, et al.
Publicado: (2021) -
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Julio Delgado, et al.
Publicado: (2021) -
EVALUATION OF THE FREQUENCY OF ARTERIAL AND VENOUS THROMBOSIS AND PREDISPOSING FACTORS IN PATIENTS USING ELTROMBOPAG
por: Derya Deniz Kurekci, et al.
Publicado: (2021) -
DIRECT ORAL ANTICOAGULANTS IN SICKLE CELL DISEASE, WHERE WE STAND AND WHERE WE ARE HEADING: A SYSTEMATIC REVIEW
por: Waail Rozi, et al.
Publicado: (2021) -
Potential value of the calibrated automated thrombogram in patients after a cerebral venous sinus thrombosis; an exploratory study
por: Myrthe M. van der Bruggen, et al.
Publicado: (2021)